Stay updated with breaking news from Partners Advancing Technology. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Data demonstrate potential of Manual Dexterity Test and Konectom smartphone-based technology in measuring MS disease progressionRetrospective analysis applying machine learning, artificial intelligence
MS PATHS data indicate that 100 percent of people with MS treated with natalizumab, interferons or fumarates achieved an antibody response following COVID-19 vaccinationData from this analysis also suggest
(diroximel fumarate) reinforce the treatment’s positive gastrointestinal tolerability profile Biogen advances leading research to help inform future patient management including new information on the clinical profile of extended interval dosing with natalizumab CAMBRIDGE, Mass., April 16, 2021 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) today announced new data from its industry-leading portfolio of multiple sclerosis (MS) therapies to be presented at the American Academy of Neurology (AAN) 2021 Virtual Annual Meeting, April 17-22. The presentations include data on quality of life b...
Biogen Inc.: New Data at AAN 2021 from Across Biogen's MS Portfolio Demonstrate Positive Impact of Treatment on People Living with Relapsing Multiple Sclerosis (natalizumab) can lead to meaningful improvements in mental and social health compared to Ocrevus (ocrelizumab) (diroximel fumarate) reinforce the treatment's positive gastrointestinal tolerability profile Biogen advances leading research to help inform future patient management including new information on the clinical profile of extended interval dosing with natalizumab CAMBRIDGE, Mass., April 16, 2021(Nasdaq: BIIB) today announc...